In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug ...

I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

2024 was pivotal for UK Life Sciences’ venture funding landscape. Softening macro and geopolitical conditions saw activity ...

From April, women invited for a routine breast cancer screening will be invited to take part in the trial at 30 testing sites ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Pharma trade organisations in the US have told President Trump that tariffs such as the 10% levy on Chinese imports could drive up the cost of generic medicines, impact supply chains, and exacerbate ...

In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

There was a standoff between USAID and Elon Musk's Department of Government Efficiency (DOGE) over access to restricted areas ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...